New blood test revolutionises colon cancer screening
New test, the Shield, tests blood for tumour markers and tumour DNA
The Food and Drug Administration (FDA) has approved the first blood test for colon cancer screening, offering a less invasive alternative to colonoscopy. This new test, called Shield, tests the blood for tumour markers and tumour DNA.
How does the SHIELD work?
The SHIELD tests a blood sample for colon cancer-specific biomarkers. These markers may include proteins and DNA fragments associated with cancer cells. The test is performed in a laboratory and the results are reported to the doctor.
Why is colon cancer screening important?
Colon cancer is one of the most common cancers. Early diagnosis is crucial to increase the chances of recovery. Colonoscopy, although effective, is often avoided because of its invasiveness and the necessary preparation.
Advantages and limitations of this new technique
This new technique for screening colon cancer has several advantages and limitations compared to traditional colonoscopy.
The advantages:
- Less invasive: A simple blood sample replaces colonoscopy
- Greater accessibility: May encourage more people to get screened
- Insurance coverage: FDA approval could lead to increased insurance coverage.
The limits are:
- Sensitivity: Although effective in detecting many cases of colon cancer, Shield may not detect all cancers, especially those at an early stage
- False positives: A positive result may require a colonoscopy to confirm the diagnosis
- No polyps: Shield cannot remove precancerous polyps as colonoscopy does
- Test frequency: It is not yet clear how often the Shield test should be repeated.
What do the experts say?
Experts agree that the SHIELD represents a step forward in the fight against colon cancer, But they stress the importance of considering different screening options based on your own needs and the doctor’s advice. Colonoscopy remains the gold standard for the removal of precancerous polyps, but the Shield could be a viable alternative for those who avoid colonoscopy.
New prospects for prevention
The approval of Shield opens new perspectives for colon cancer screening, making it more accessible and less invasive. However, it is crucial to carefully weigh the pros and cons of each screening option with your doctor. The choice of the most suitable test depends on individual preferences, family history and personal risk.